GENOMICA is a spanish biotechnology company founded in 1990, and located in Madrid. GENOMICA is characterized by its innovation, commitment and flexibility to adapt to market needs and for being a pioneer in offering constant responses to critical situations.
GENOMICA commercializes its own CLART microarray technology, which is applied to the molecular diagnosis of infectious diseases, to personalized medicine and to the detection of biomarkers in oncology: HPV, STDs, Herpes, Sepsis, Gastrointestinal and Respiratory Infections, and Cancer Mutation Analysis. In addition, GENOMICA develops and commercialize Real Time PCR kits for Covid-19, Covid-19+FluA+FluB+RSV and FluA+FluB+RSV. GENOMICA will launch soon an innovative CLART technology, FASTCLART, for Respiratory infection, for detection and identification of 24 viruses including SARS-CoV-2. GENOMICA also offers different platforms to automate CLART technology (AutoCLART).
GENOMICA is currently present in more than 30 countries. GENOMICA has subsidiaries in Sweden and China and commercial delegates in different geographical areas.